Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Detalles Bibliográficos
Autores principales: Medisetty, Mahender Kumar, Patel, Atul, Pujari, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883703/
https://www.ncbi.nlm.nih.gov/pubmed/33601033
http://dx.doi.org/10.1016/j.ijid.2021.02.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883703/
https://www.ncbi.nlm.nih.gov/pubmed/33601033
http://dx.doi.org/10.1016/j.ijid.2021.02.035

Ejemplares similares